Home/Pipeline/aGF

aGF

Osteoarthritis

Phase 1Active

Key Facts

Indication

Osteoarthritis

Phase

Phase 1

Status

Active

Company

Scarcell Therapeutics

About Scarcell Therapeutics

Scarcell Therapeutics is a clinical-stage biotech developing an allogenic gingival fibroblast (aGF) platform for regenerative medicine, initially targeting osteoarthritis. Its lead candidate, aGF, is a single-injection therapy with demonstrated safety and efficacy in over 800 companion animals and is preparing for Phase Ib human trials in Europe in mid-2025. The company's technology leverages the immune-tolerant properties of gingival fibroblasts to enable long-lasting effects without immunosuppression, positioning it as a potential disease-modifying therapy in a large, underserved market.

View full company profile

Therapeutic Areas

Osteoarthritis Degenerative Diseases Inflammatory Diseases

Other Osteoarthritis Drugs

Drug	Company	Phase	Status
MSC‑OA	Advancells	Phase 1	Active
Osteoarthritis program	Risen Pharma Tech	Clinical (China & US)	Active
ViscoCell™ for Osteoarthritis	Likarda	Pre-clinical	Active
Osteoarthritis Biologic Therapy	Ageless Biotech	Phase 2b	Active
PKM-011	PK MED	Pre-clinical	Active
CYT-108	Cytonics	Phase 2	Active
Topical PSGAG	ADORA Life Science	Pre-clinical	Active
FGF18 Gene Therapy	Remedium Bio	Pre-clinical	Active
MOTYS™	Doron Therapeutics	Phase 3	Active
Osteoarthritis Treatment Program	Biovico	Pre-clinical	Active
Cartilage Repair	Sayenza Biosciences	Clinical	Active
BRM521	BRIM Biotechnology	Preclinical	Active